Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury

Experimental Neurology

Volumn 282, Issue , 2016, Pages 49-55

  Zhang, Gang ^a   Massaad, Cynthia A ^a   Gao, Tong ^a   Pillai, Laila ^a   Bogdanova, Nataliia ^a   Ghauri, Sameera ^a   Sheikh, Kazim A ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Guillain Barr syndrome; IL 33; IL 4; IVIg; SIGN R1; SIVIg; Th2 pathway

Indexed keywords

BINDING PROTEIN; FC RECEPTOR; GANGLIOSIDE ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 33; INTERLEUKIN 4; SPECIFIC ICAM3 GRABBING NONINTEGRIN RELATED 1 RECEPTOR; UNCLASSIFIED DRUG; ANTIBODY; GANGLIOSIDE; IMMUNOGLOBULIN; IMMUNOLOGIC FACTOR; MESSENGER RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL SCIATIC NERVE INJURY; GENE EXPRESSION REGULATION; GUILLAIN BARRE SYNDROME; IL 33 GENE; INHIBITION KINETICS; INNATE IMMUNITY; MOUSE; NERVE FIBER REGENERATION; NERVE REGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE INJURY; SIALYLATION; TH2 CELL; UPREGULATION; ANIMAL; C57BL MOUSE; CONVALESCENCE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY; METABOLISM; SCIATIC NEUROPATHY; TIME FACTOR;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GANGLIOSIDES; GENE EXPRESSION REGULATION; GUILLAIN-BARRE SYNDROME; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INTERLEUKIN-33; MICE; MICE, INBRED C57BL; NERVE REGENERATION; RECOVERY OF FUNCTION; RNA, MESSENGER; SCIATIC NEUROPATHY; TIME FACTORS;

EID: 84969622379     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2016.05.020     Document Type: Article

References (40)

1. Anthony R.M., Nimmerjahn F., Ashline D.J., Reinhold V.N., Paulson J.C., Ravetch J.V. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
2. Anthony R.M., Wermeling F., Karlsson M.C., Ravetch J.V. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19571-19578.
3. Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011, 475:110-113.
4. Anthony R.M., Wermeling F., Ravetch J.V. Novel roles for the IgG Fc glycan. Ann. N. Y. Acad. Sci. 2012, 1253:170-180.
5. Arnold J.N., Wormald M.R., Sim R.B., Rudd P.M., Dwek R.A. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu. Rev. Immunol. 2007, 25:21-50.
6. Asbury A.K., Arnason B.G., Adams R.D. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969, 48:173-215.
7. Bayry J., Kazatchkine M.D., Kaveri S.V. Shortage of human intravenous immunoglobulin-reasons and possible solutions. Nat. Clin. Pract. Neurol. 2007, 3:120-121.
8. Dalakas M.C. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat. Rev. Neurol. 2011, 7:507-517.
9. Griffin J.W., Stoll G., Li C.Y., Tyor W.R., Cornblath D.R. Macrophage responses in inflammatory demyelinating neuropathies. Ann. Neurol. 1990, 27(Suppl.):S64-S68.
10. Hafer-Macko C., Hsieh S.-T., Li C.Y., Ho T.W., Sheikh K., Cornblath D.R., McKhann G.M., Asbury A.K., Griffin J.W. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 1996, 40:635-644.
11. He L., Zhang G., Liu W., Gao T., Sheikh K.A. Anti-ganglioside antibodies induce nodal and axonal injury via Fcgamma receptor-mediated inflammation. J. Neurosci. 2015, 35:6770-6785.
12. Hogarth P.M. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 2002, 14:798-802.
13. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
14. Hughes R.A., Hadden R.D., Gregson N.A., Smith K.J. Pathogenesis of Guillain-Barré syndrome. J. Neuroimmunol. 1999, 100:74-97.
15. Ilyas A.A., Willison H.J., Quarles R.H., Jungalwala F.B., Cornblath D.R., Trapp B.D., Griffin D.E., Griffin J.W., McKhann G.M. Serum antibodies to gangliosides in Guillain-Barré syndrome. Ann. Neurol. 1988, 23:440-447.
16. Kaneko Y., Nimmerjahn F., Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
17. Kessary-Shoham H., Levy Y., Shoenfeld Y., Lorber M., Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J. Autoimmun. 1999, 13:129-135.
18. Kiefer R., Kieseier B.C., Stoll G., Hartung H.P. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog. Neurobiol. 2001, 64:109-127.
19. Lehmann H.C., Lopez P.H.H., Zhang G., Ngyuen T., Zhang J.Y., Kieseier B.C., Mori S., Sheikh K.A. Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model. J. Neurosci. 2007, 27:27-34.
20. Lunn M.P., Johnson L.A., Fromholt S.E., Itonori S., Huang J., Vyas A.A., Hildreth J.E., Griffin J.W., Schnaar R.L., Sheikh K.A. High-affinity anti-ganglioside IgG antibodies raised in complex ganglioside knockout mice: reexamination of GD1a immunolocalization. J. Neurochem. 2000, 75:404-412.
21. McKhann G.M., Cornblath D.R., Griffin J.W., Ho T.W., Li C.Y., Jiang Z., Wu H.S., Zhaori G., Liu Y., Jou L.P., Liu T.C., Gao C.Y., Mao J.Y., Blaser M.J., Mishu B., Asbury A.K. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 1993, 33:333-342.
22. Nguyen T.P., Biliciler S., Wahed A., Sheikh K. Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg. Neurol. Neuroimmunol. Neuroinflammation 2014, 1:e50.
23. Nimmerjahn F., Ravetch J.V. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 2008, 8:34-47.
24. Ogawara K., Kuwabara S., Mori M., Hattori T., Koga M., Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann. Neurol. 2000, 48:624-631.
25. Prineas J.W. Pathology of the Guillain-Barré syndrome. Ann. Neurol. 1981, 9(Suppl.):6-19.
26. Quarles R.H., Ilyas A.A., Willison H.J. Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. Ann. Neurol. 1990, 27(Suppl.):S48-S52.
27. Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001, 291:484-486.
28. Schnaar R.L., Fromholt S.E., Gong Y., Vyas A.A., Laroy W., Wayman D.M., Heffer-Lauc M., Ito H., Ishida H., Kiso M., Griffin J.W., Sheikh K.A. IgG-class mouse monoclonal antibodies to major brain gangliosides. Anal. Biochem. 2002, 302:276-284.
29. Schwab I., Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 2013, 13:176-189.
30. Tackenberg B., Jelcic I., Baerenwaldt A., Oertel W.H., Sommer N., Nimmerjahn F., Lunemann J.D. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:4788-4792.
31. Tackenberg B., Nimmerjahn F., Lunemann J.D. Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy. J. Clin. Immunol. 2010, 30(Suppl. 1):S65-S69.
32. Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
33. Washburn N., Schwab I., Ortiz D., Bhatnagar N., Lansing J.C., Medeiros A., Tyler S., Mekala D., Cochran E., Sarvaiya H., Garofalo K., Meccariello R., Meador J.W., Rutitzky L., Schultes B.C., Ling L., Avery W., Nimmerjahn F., Manning A.M., Kaundinya G.V., Bosques C.J. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E1297-E1306.
34. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002, 125:2591-2625.
35. Yuki N., Hartung H.P. Guillain-Barré syndrome. N. Engl. J. Med. 2012, 366:2294-2304.
36. Yuki N., Yamada M., Koga M., Odaka M., Susuki K., Tagawa Y., Ueda S., Kasama T., Ohnishi A., Hayashi S., Takahashi H., Kamijo M., Hirata K. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 2001, 49:712-720.
37. Yuki N., Susuki K., Koga M., Nishimoto Y., Odaka M., Hirata K., Taguchi K., Miyatake T., Furukawa K., Kobata T., Yamada M. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11404-11409.
38. Zhang G., Lopez P.H., Li C.Y., Mehta N.R., Griffin J.W., Schnaar R.L., Sheikh K.A. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain 2004, 127:1085-1100.
39. Zhang G., Lehmann H.C., Manoharan S., Hashmi M., Shim S., Ming G.L., Schnaar R.L., Lopez P.H., Bogdanova N., Sheikh K.A. Anti-ganglioside antibody-mediated activation of RhoA induces inhibition of neurite outgrowth. J. Neurosci. 2011, 31:1664-1675.
40. Zhang G., Bogdanova N., Gao T., Song J.J., Cragg M.S., Glennie M.J., Sheikh K.A. Fcgamma receptor-mediated inflammation inhibits axon regeneration. PLoS One 2014, 9:e88703.